BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) EVP Aby J. Mathew sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $22.14, for a total transaction of $221,400.00. Following the sale, the executive vice president now owns 273,118 shares of the company’s stock, valued at $6,046,832.52. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
BioLife Solutions Price Performance
Shares of BioLife Solutions stock opened at $22.40 on Friday. The company has a current ratio of 2.81, a quick ratio of 1.93 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average of $20.05 and a 200 day moving average of $21.04. BioLife Solutions, Inc. has a 1 year low of $12.10 and a 1 year high of $26.96.
BioLife Solutions (NASDAQ:BLFS – Get Rating) last issued its quarterly earnings results on Thursday, March 16th. The medical equipment provider reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03). BioLife Solutions had a negative return on equity of 8.20% and a negative net margin of 89.08%. The business had revenue of $44.26 million during the quarter, compared to the consensus estimate of $43.34 million. As a group, analysts anticipate that BioLife Solutions, Inc. will post -0.41 EPS for the current fiscal year.
Analysts Set New Price Targets
Institutional Trading of BioLife Solutions
Several institutional investors have recently bought and sold shares of BLFS. BlackRock Inc. grew its position in BioLife Solutions by 10.7% during the 3rd quarter. BlackRock Inc. now owns 5,416,115 shares of the medical equipment provider’s stock valued at $123,217,000 after purchasing an additional 522,912 shares during the last quarter. Millennium Management LLC grew its position in BioLife Solutions by 45.3% during the 2nd quarter. Millennium Management LLC now owns 1,560,137 shares of the medical equipment provider’s stock valued at $21,545,000 after purchasing an additional 486,631 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of BioLife Solutions by 64.6% during the 4th quarter. Jennison Associates LLC now owns 993,239 shares of the medical equipment provider’s stock valued at $18,077,000 after acquiring an additional 389,812 shares during the last quarter. Fred Alger Management LLC boosted its holdings in shares of BioLife Solutions by 21.9% during the 3rd quarter. Fred Alger Management LLC now owns 2,163,476 shares of the medical equipment provider’s stock valued at $49,219,000 after acquiring an additional 388,642 shares during the last quarter. Finally, Bessemer Group Inc. purchased a new stake in shares of BioLife Solutions during the 3rd quarter valued at about $8,673,000. 89.82% of the stock is owned by hedge funds and other institutional investors.
BioLife Solutions Company Profile
BioLife Solutions, Inc engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services.
- Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.